Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

Next Previous
Search
Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGDM1400 (Primary) ; PGT 121 (Primary) ; TMB-380 (Primary) ; Zinlirvimab (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 02 Aug 2022 Results of clinical data comparing VRC07-523LS pharmacokinetics when administered alone (HVTN 127/HPTN 087) versus co-administered with other bnAbs that bind non-overlapping HIV Env epitopes, including V2-binding PGDM1400 and V3-binding 10-1074 and PGT121 (HVTN 130/HPTN 089), presented at the 24th International AIDS Conference.
    • 12 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top